Sedative-hypnotic Effect of Ash of Silver in Mice: A Reverse Pharmacological Study

Deep Inder¹, Pawan Kumar²

¹Department of Pharmacology, FOD, Jamia Millia Islamia, New Delhi, India.
²Department of Community Health Administration, National Institute of Health and Family Welfare, Munirka, New Delhi, India.

ABSTRACT

Ash of silver is used in traditional systems of medicine for various neurological conditions like insomnias, neuralgias, anxiety disorders, and convulsions. The present study was conducted to evaluate the sedative-hypnotic activity of ash of silver in comparison to pentobarbitone (standard drug) in albino mice. The mice were divided into four groups as follows: Group 1 (control): Gum acacia [GA; 1% per os (p.o.)], group 2 (standard): Pentobarbitone [50 mg/kg intraperitoneal (i.p.)], group 3 (test): Ash of silver (50 mg/kg p.o.), and group 4: Ash of silver (50 mg/kg p.o.) given 30 min prior to administration of pentobarbitone (50 mg/kg i.p.). Time of onset, recovery, and total duration of loss of righting reflex were studied. Ash of silver (test) produced significant sedation (P < 0.01) compared to control (GA 1%), but the effect was significantly less compared to that of standard pentobarbitone at the doses used. Also, significant potentiation (P < 0.001) of the sedative-hypnotic effect of pentobarbitone was observed with the test drug.

Key words: Ash of silver, Pentobarbitone, Sedation
Kusta Nukras, etc.) have been used for the treatment of rheumatoid arthritis, acute pro-myelo cytic leukemias, immunostimulation, and as analgesics in painful inflammatory conditions, and are prescribed with accompaniments such as ginger or cumin water, tulsi extract, lemon extract, etc., that have been shown to protect against unwanted toxicity due to various reasons which include high proportions of trace elements and have synergistic or protective effects due to buffering between various constituents or free radical scavenging property. Oxides of heavy metals are usually not toxic, as claimed by Rasa Shastra. [2,10,11]

Since the safety of ash of silver has already been established, reverse pharmacological studies are required to confirm the established facts regarding usage, safety, and efficacy in various clinical conditions mentioned above. Since raw silver ore is considered hazardous for health as mentioned in Ayurvedic literature, it needs to be converted into non-harmful form (ash of silver) by the process of trituration, pulverization, and repeated calcinations (at 300°C) for 14 times. Reduced form of silver thus obtained acquires spherical nanostructure with a size of 16 nm without any change in the morphology of silver, and is now called as ash of silver. [4,7] Nanosize of the silver particle is probably responsible for improving the penetration of silver in brain; hence, ash of silver had been used in the past for treatment of various neurological conditions, viz. insomnia, anxiety, and pain. [9,10] Being a heavy metal preparation, ash of silver bears cumulative potential after prolonged use and in overdoses, as seen in preliminary animal studies. After certain controversial reports of toxicity due to use of metallic/elemental drugs, it has now been made mandatory (WHO guidelines) that Ayurvedic drugs in any form should be tested for their heavy metal content prior to export, so that heavy metals remain within permissible limits. [11-13]

This study was conducted with an aim (a) to explore the sedative-hypnotic effect of ash of silver, if any, as claimed in Ayurvedic literature. Further, if ash of silver showed sedative-hypnotic effect, the study aimed (b) to observe whether the test drug ash of silver was potentiating the sedative-hypnotic effect of pentobarbitone at the doses used in mice when given 30 min prior to the standard drug.

**MATERIALS AND METHODS**

Swiss albino mice of either sex weighing between 20 and 30 g were screened for the study, after obtaining approval from the Institutional Animal Ethics Committee. Mice were fed on a standard pellet diet and water ad libitum, and were housed in polypropylene cages under similar environmental conditions in an animal room that was maintained at 24 ± 1°C and 55 ± 5% humidity with a 12 h light–dark cycle throughout the experiment. In case of oral administration, mice were fasted for 12 h before testing. Plexiglass chamber was used to observe the responses of mice.

**Drugs and dosage forms**

The test drug ash of silver was procured from M/s Baidyanath Ayurved Bhawan Ltd (Jhansi, India). Ash of silver [50 mg/kg per os (p.o.)] was suspended in 1% solution of gum acacia. Gum acacia (1% p.o.), procured from Arora Pharmacy (New Delhi, India), was labeled as control and was administered in a volume of 1 ml/100 g. Ash of silver and gum acacia were administered orally using infant feeding pipe with a 1 ml syringe attached at the other end. Standard sedative-hypnotic pentobarbitone [50 mg/kg intraperitoneal (i.p.)] was procured from Nembutal Dainippon Pharmaceutical Co. (Osaka, Japan) and was administered as i.p. injection using 1 ml syringe.

**Animals and their grouping**

Animals (mice) were divided into four groups consisting of six animals in each. Study protocol was as follows:

- **Group 1**: Received vehicle gum acacia (1% p.o.) as control, given in a volume of 1 ml/100 g p.o.
- **Group 2**: Received pentobarbitone (50 mg/kg i.p.) as the standard drug.
- **Group 3**: Received the test drug ash of silver (50 mg/kg p.o.) suspended in 1% solution of gum acacia.
- **Group 4**: Received the test drug ash of silver (50 mg/kg p.o.) suspended in 1% solution of gum acacia, following which the standard drug pentobarbitone (50 mg/kg i.p.) was given after 30 min.

The responses of all drugs [in terms of time of onset, time of recovery, and total duration of loss of righting reflex (LORR) in mice] were assessed by continuous observation of animals throughout the experiments from the time of administration of drug in the plexiglass chamber, using a stop watch.

**Measurement of the duration of pentobarbital-induced LORR**

The duration of LORR was measured according to the procedures described by Marley et al. [14] Mice were given an i.p. injection of pentobarbitone (50 mg/kg). When the mice became ataxic, they were placed on their backs on a pre-warmed (37°C) pad and the onset, recovery, and total duration of LORR [starting at the time of administration of the test drug (ash of silver), the standard drug pentobarbitone (50 mg/kg), and the test drug (ash of silver)] followed 30 min later by the standard drug pentobarbitone (50 mg/kg)] were noted until they regained their righting reflexes. Mice were presumed to have regained the righting response when they could right themselves three times within 30 sec.

**RESULTS**

Findings of the present study are depicted in Table 1. All values were expressed as Mean ± SEM and analyzed using analysis of variance (ANOVA) followed by Dunnett’s “t” test. *P < 0.05* was considered significant.

**DISCUSSION**

In the present study, we tried to explore the pharmacological effect of ash of silver as a sedative-hypnotic and its secondary effect to potentiate the sedative-hypnotic effect of pentobarbitone. Such studies help to fast track drug discovery and development when carried out in selected animal models through screening. Thus, Ayurvedic knowledge and experimental database are able to provide new functional leads, thereby reducing the toxicity of drugs and saving time and money. [13]
Table 1. Effects of various drug treatments on sleep in mice

<table>
<thead>
<tr>
<th>Group no. (n=6 in each group)</th>
<th>Drug treatment with dose and route of administration</th>
<th>Righting reflex in mice (in min) (mean±SEM)</th>
<th>Time of onset of loss of righting reflex (O)</th>
<th>Time of recovery (R)</th>
<th>Total duration of loss of righting reflex (R-O)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Vehicle, gum acacia (1% p.o.)</td>
<td>No effect seen</td>
<td>No effect seen</td>
<td>No effect seen</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Pentobarbitone sodium (50 mg/kg i.p.)</td>
<td>11.83±0.74**</td>
<td>33.13±0.43**</td>
<td>21.33±0.57**</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Ash of silver (50 mg/kg p.o.)</td>
<td>29.33±0.99*</td>
<td>40.07±0.68*</td>
<td>10.74±0.52*</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Ash of silver (50 mg/kg p.o.) + pentobarbitone sodium (50 mg/kg i.p.)</td>
<td>9.78±0.48**</td>
<td>37.10±0.57**</td>
<td>27.32±0.61**</td>
<td></td>
</tr>
</tbody>
</table>

**P<0.001(highly significant), *P<0.01(statistically significant)**

In the present study, *ash of silver* was observed to possess sedative effect at a dose of 50 mg/kg (p.o.) in mice. The sedative effect was significant ($P < 0.01$) when compared with the vehicle gum acacia (1% p.o.) in mice. The sedative effect of the test drug *ash of silver* was significantly less ($P < 0.01$) compared to pentobarbitone (50 mg/kg i.p.), the standard drug ($P < 0.001$). Significant potentiation ($P < 0.001$) of the sedative-hypnotic effect of pentobarbitone (50 mg/kg i.p.) was observed with 30 min prior administration of the test drug *ash of silver* (50 mg/kg p.o.).

The above findings reveal that *ash of silver* had sedative effect at the doses used; therefore, it can be proposed that *ash of silver* might be acting as a sedative-hypnotic owing to its pharmacological effects probably mediated by inhibition of neuropeptide S (NPS) or N-methyl-d-aspartate (NMDA)/histamine/5-HT3/dopamine or potentiation of effects mediated through gamma-aminobutyric acid (GABA)/glycine or benzodiazepines (BZDs)/opioid receptors. NPS was recently identified as the endogenous ligand of an orphan receptor, now referred to as the NPS receptor. *In vivo*, NPS produces a unique behavioral profile by increasing wakefulness and exerting anxiolytic-like effects.[15-19]

To explore the mechanism of action of *ash of silver* as a sedative, antagonists/blockers need to be administered against the above-mentioned mediators. In our previous study, we tried to explore the analgesic activity of *ash of silver*, which is probably mediated through opioid receptors as it was observed after administering naloxone, the opioid antagonist, although the role of other mediators cannot be ruled out.[13] One of the studies has proposed that ashes of heavy metals used in traditional systems of medicine function as a catalyst by their presence in intestine, plasma, and blood, thereby acting as free radical scavengers.[8,10,11] Ash particles of heavy metals (gold, silver) in calcined form, being insoluble, exist as nanoparticles (16 nm), which are very tiny particles and bioavailable, and therefore can cross the blood–brain barrier to exert various central actions as claimed in Ayurvedic literature, viz. analgesic, anti-inflammatory, sedative, anti-anxiety, cognitive, neuroleptic, and antiepileptic.[4-7,11,20] Lankveld et al. and Kim et al. have proved the distribution of nanosized silver particles in the central nervous system as well as in other tissues, e.g., liver, kidney and spleen, and intestine, when administered by the oral route.

As the findings of our study have shown significant potentiation of sedative-hypnotic effect of pentobarbitone with 30 min prior administration of *ash of silver* at the dose used, it can be hypothesized that there is a possibility of *ash of silver* acting as hepatic cytochrome P450 microsomal enzyme inhibitor. Further, it can be hypothesized that *ash of silver* increases the plasma levels of pentobarbitone by inhibiting its hepatic metabolism, so as to potentiate the sedative/anesthetic effect of pentobarbitone. Pentobarbitone is mainly metabolized in the liver. Further studies are required to confirm and establish this fact also by intracerebroventricular injection of *ash of silver* in the brain of mouse/rats.

Till date, hardly any studies have been conducted to explore the pharmacological effects of *ash of silver* on sedation/sleep in human body, in spite of its wide use in humans in Ayurvedic practice for many centuries. Studies conducted by Nadeem et al. on silver preparations showed their interesting anti-anxiety, anti-catecholic, and anti-aggressive effects. No scientific reports are available to confirm these claims except for some preliminary experimental studies demonstrating slight diminution of discharge frequency in frog nerve-muscle preparation bathed in 3% suspension of *ash of silver*. The anti-anxiety and anti-aggressive effects observed by Nadeem et al. support the nerve-soothing properties (nervine tonic) of silver preparations.[11]

In one study, there is a mention of phytochelatins (PCs), produced from reduced glutathione present in green plants and legumes, which tend to chelate the heavy metals from soil. Therefore, it can be postulated that in the presence of vegetarian diet, a fraction of *ash of silver* is also liable to get chelated if taken with vegetarian food.[21-23] Also, the same theory can be applied to overcome the toxic effects produced by excess dose of *ash of silver*, as mentioned in the study of Inder et al. Pharmacokinetic and pharmacodynamic studies need to be carried out to find if there is any interaction of *ash of silver* if taken with vegetarian diet, so as to formulate and revise the dose for human use. The role of free radical scavengers needs to be established, which can help to reduce the adverse effects of *ash of silver*. One of the studies has shown the interaction of *ash of silver* with some biomolecules, proteins, vitamins, etc., thus affecting various physiological reactions.[24-28] From the observations and results of the study with the test drug *ash of silver*, it can be postulated that at the doses used in mice (50 mg/kg p.o.), it acts as a mild to moderate sedative and owing to this property, it might have potentiated the duration of LORR effect of pentobarbitone (50 mg/kg i.p.), i.e., synergistic effect. But as both these drugs are metabolized by the liver to a greater extent, inhibition of cytochrome P450 enzymes system in the liver by *ash of silver* cannot be ruled out, which is probably responsible for inhibiting the hepatic metabolism of pentobarbitone resulting in high plasma levels of pentobarbitone, which might have potentiated the sedative-hypnotic effect of pentobarbitone at the doses used in mice.
CONCLUSION

Ash of silver possesses significant sedative hypnotic potential at a dose used in present animal study. Therefore it can serve as a better alternative as sleep inducing drug with a better safety profile compared to conventional hypnotics. Further studies will provide adequate data to support this evidence.

ACKNOWLEDGMENT

We are thankful to Dr. (Professor) Vijay Kumar Bajaj for the constant guidance, supervision, and valuable suggestions during this study.

REFERENCES